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AbstrACt
Introduction Timing of cord clamping and other cord 
management strategies may improve outcomes at preterm 
birth. However, it is unclear whether benefits apply to all 
preterm subgroups. Previous and current trials compare 
various policies, including time- based or physiology- based 
deferred cord clamping, and cord milking. Individual 
participant data (IPD) enable exploration of different 
strategies within subgroups. Network meta- analysis 
(NMA) enables comparison and ranking of all available 
interventions using a combination of direct and indirect 
comparisons.
Objectives (1) To evaluate the effectiveness of cord 
management strategies for preterm infants on neonatal 
mortality and morbidity overall and for different participant 
characteristics using IPD meta- analysis. (2) To evaluate 
and rank the effect of different cord management 
strategies for preterm births on mortality and other key 
outcomes using NMA.
Methods and analysis Systematic searches of Medline, 
Embase, clinical trial registries, and other sources for 
all ongoing and completed randomised controlled trials 
comparing cord management strategies at preterm birth 
(before 37 weeks’ gestation) have been completed up 
to 13 February 2019, but will be updated regularly to 
include additional trials. IPD will be sought for all trials; 
aggregate summary data will be included where IPD are 
unavailable. First, deferred clamping and cord milking will 
be compared with immediate clamping in pairwise IPD 
meta- analyses. The primary outcome will be death prior to 
hospital discharge. Effect differences will be explored for 
prespecified participant subgroups. Second, all identified 
cord management strategies will be compared and 
ranked in an IPD NMA for the primary outcome and the 
key secondary outcomes. Treatment effect differences by 
participant characteristics will be identified. Inconsistency 
and heterogeneity will be explored.
Ethics and dissemination Ethics approval for this 
project has been granted by the University of Sydney 
Human Research Ethics Committee (2018/886). Results 
will be relevant to clinicians, guideline developers and 
policy- makers, and will be disseminated via publications, 
presentations and media releases.
registration number Australian New Zealand Clinical 
Trials Registry (ANZCTR) (ACTRN12619001305112) and 
International Prospective Register of Systematic Reviews 
(PROSPERO, CRD42019136640).
IntrOduCtIOn
Currently over 15 million babies are born 
preterm annually and this number is rising.1–3 
Of these, 1.1 million die, and the morbidity 
strengths and limitations of this study
 ► This will be the most comprehensive review to date 
of interventions for umbilical cord management in 
preterm infants and the findings will be highly rele-
vant to clinicians and guideline developers.
 ► The use of individual participant data will allow as-
sessment of the best treatment option for key sub-
groups of participants.
 ► Network meta- analysis will enable the comparison 
and ranking of all available treatment options using 
direct and indirect evidence.
 ► For some of the trials it will not be possible to obtain 
individual participant data, so published aggregate 
results will be used instead.
 ► Risk of bias in the primary trials will be assessed 
using Cochrane criteria, and certainty of evidence 
for the meta- analyses will be appraised using the 
GRADE (Grading of Recommendations Assessment, 
Development and Evaluation) approach for the pair-
wise comparisons, and the CINeMA (Confidence in 
Network Meta- Analysis) approach for the network 
meta- analysis.
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and healthcare costs among survivors and their families 
are high, with preterm survivors having an increased risk 
of cognitive, developmental and behavioural difficulties, 
and chronic ill health.4–9 Hence, even modest improve-
ments in outcomes of preterm birth would substantially 
benefit the children, their families and also health services. 
In uncompromised babies, deferring cord clamping has 
been shown to be beneficial and is now used in routine 
practice.10 However, it is unclear whether these benefits 
apply to preterm babies who usually receive immediate 
neonatal care, and whether any benefits outweigh poten-
tial harms. In addition, there are multiple competing 
cord management strategies, such as clamping the cord 
at different times or milking the cord, and consider-
ations of the infant’s respiratory status, and it is currently 
unknown which strategy yields the best balance of bene-
fits and harms.
Current approaches to cord clamping
One potential mechanism of deferring umbilical cord 
clamping is a net transfer of blood from the placenta to 
the baby known as ‘placental transfusion’. If the cord is 
not clamped at birth immediately, blood flow between the 
placenta and the baby may continue for up to 5 min in term 
infants.11–13 For preterm births, blood flow may continue 
for longer,14 since a greater proportion of fetoplacental 
circulating blood volume is still in the placenta.15 This has 
led to time- based approaches to deferring cord clamping 
that have been shown to increase peak haematocrit and 
reduce the need for blood transfusions.16 Yet, recent find-
ings suggest that placental transfusion does not always 
occur—blood flow may continue without any net transfer, 
and sometimes net transfer may be to the placenta.17 
Initial neonatal care and stabilisation traditionally takes 
place on a resuscitation platform at the side of the room 
or in an adjacent room. Deferred cord clamping is thus 
often associated with a delay in neonatal care and this has 
led to concerns including delayed resuscitation and hypo-
thermia18 particularly for very preterm infants and infants 
assessed as requiring resuscitation. An alternate emerging 
strategy is to provide immediate neonatal care with the 
cord intact beside the woman using a mobile resuscita-
tion trolley or on the mother’s leg.19–23
Another potential mechanism of deferred clamping 
is allowing time for the infant to establish spontaneous 
breathing while still placentally supported. Immediate 
cord clamping before the infant has established breathing 
may be harmful since it can lead to large fluctuations in 
blood pressure, a period of hypoxia and restricted cardiac 
function.24 Animal and pilot human studies suggest 
that breathing and lung aeration before cord clamping 
can improve cardiovascular stability and oxygenation, 
and reduce intraventricular haemorrhage and infant 
mortality.25–28 They also suggest that initial respiratory 
support before clamping the cord can improve cere-
bral oxygenation and blood pressure, and reduce cere-
brovascular impairment compared with immediate 
cord clamping.29 30 This evidence has led to the rise of 
‘physiological cord clamping’ which defers clamping until 
after the onset of breathing. Yet, onset of breathing is not 
always easy to determine without the assistance of video 
or extra equipment, while timing to cord clamping can 
be easily measured. In an earlier study,31 time of onset of 
breathing in preterm infants receiving gentle stimulation 
was related to time after birth—within a minute over 90% 
of preterm infants had begun spontaneous breathing.
Cord milking or stripping (pinching the umbilical cord 
close to the mother and moving the fingers towards the 
infant) may be a way to increase preterm blood volume 
without deferring clamping.32 Yet, a preterm lamb model 
demonstrated that during cord milking there was a tran-
sient increase of carotid blood flow and pressure.33 A 
recent trial comparing deferred cord clamping with cord 
milking was stopped early in the subgroup of extremely 
preterm infants (23–27 weeks), as the incidence of severe 
intraventricular haemorrhage was higher in the cord 
milking group.34 Hence, the effect of cord milking in 
different populations needs further elucidation.
Current guidelines for cord management at birth and previous 
reviews of aggregate data
Current uncertainties in optimal cord management 
strategies are reflected in varying guidelines. The WHO 
recommends late cord clamping35 unless resuscita-
tion is required, the National Institute for Health and 
Care Excellence (NICE) recommends waiting for 30 s 
to 3 min if mother and baby are stable,36 and the Inter-
national Liaison Committee on Resuscitation Council 
(ILCOR) recommends a delay in cord clamping of at 
least 1 min. If the baby is assessed as requiring resuscita-
tion (which is the case in many preterm infants),37 WHO 
recommends immediate clamping,38 NICE recommends 
considering cord milking before clamping and ILCOR 
concludes that there is insufficient evidence to make any 
recommendations.37
A 2012 Cochrane review of timing of cord clamping for 
preterm births39 included 15 trials, with 738 infants, of 
which one trial (with 40 infants) compared cord milking 
with immediate cord clamping.32 There was heteroge-
neity in the timing of cord clamping and gestational age 
at recruitment, and data were insufficient for reliable 
conclusions about any of the primary outcomes of the 
review. A systematic review and meta- analysis published in 
2018 (including 18 trials with 2834 infants) compared the 
effect of deferred (≥30 s) versus early (<30 s) clamping in 
preterm infants, and found a reduction in the primary 
outcome of hospital mortality by 32% (risk ratio=0.68, 
95% CI 0.52 to 0.90).16 There was heterogeneity in the 
definition of ‘early cord clamping’ ranging from less than 
5 s to 25 s, and ‘late cord clamping’, ranging from 30 s to 
180 s. Recruitment age varied from 22 weeks to 36 weeks' 
gestational age. Most analyses of infant and maternal 
morbidity were substantially underpowered.16 The review 
concluded that while there is high quality evidence that 
deferred cord clamping improves outcomes, individual 
participant data (IPD) analyses are urgently needed to 
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further understand the benefits and potential harms of 
different cord management strategies, and to understand 
whether differential treatment options are advantageous 
for key subgroups of infants.16
This ongoing uncertainty about the optimal cord 
management strategy, and differential cord management 
strategies for key subgroups of infants (eg, for those 
for which resuscitation and/or stabilisation is deemed 
necessary, or extremely preterm infants) has led to 117 
planned, ongoing or published trials (in more than 
15 000 preterm babies) that are comparing a range of 
cord management strategies. IPD meta- analysis is the gold 
standard for combining such trial data. IPD provides 
larger statistical power for estimation of treatment 
effects of rarer secondary endpoints and enables reliable 
subgroup analyses to examine hypotheses about differ-
ences in treatment effect, exploring interactions between 
treatment- level and participant- level characteristics.40 
Network meta- analysis (NMA) facilitates data synthesis when 
there is a range of interventions available and permits 
indirect comparisons across all interventions by inferring 
the relative effectiveness of two competing treatments 
through a common comparator.41 42 NMA produces rela-
tive effect estimates for each intervention compared with 
every other intervention in the network. These effect sizes 
can be used to obtain rankings of the effectiveness of the 
interventions.43 Using IPD in NMA (as opposed to aggre-
gate data) can improve precision, increase information 
and reduce bias.44
Objectives
The aims of this study are:
1. To evaluate the effectiveness of cord management 
strategies for preterm infants on neonatal mortality 
and morbidity, and to evaluate patient- level modifiers 
of treatment effect.
2. To evaluate, compare and rank the effectiveness of dif-
ferent cord management strategies for preterm infants 
on mortality and the key secondary outcomes intraven-
tricular haemorrhage (any grade) and infant blood 
transfusions (any).
MEthOds And AnAlysIs
We will conduct a systematic review of randomised trials 
with IPD using pairwise meta- analysis and NMA, and a 
nested prospective meta- analysis. The lead investigator 
for all potentially eligible studies will be contacted and 
invited to collaborate and join the IPD Cord Management 
at Preterm birth (iCOMP) Collaboration. Eligible trials 
identified up to February 2019 are listed in online supple-
mentary file 1. The Collaboration will undertake this 
project according to the methods recommended by the 
Cochrane IPD, Multiple Interventions, and Prospective 
Meta- Analysis Methods Groups.40 45 46 Reporting guide-
lines for NMA protocols by Chaimani et al47 and Preferred 
Reporting Items for Systematic Reviews and Meta- Analysis 
(PRISMA) extension for protocols48 49 have been followed 
for reporting (PRISMA- Protocols (PRISMA- P) checklist 
provided in online supplementary file 2).
Eligibility criteria
Types of studies
Studies will be included if they are randomised trials. 
Cluster- randomised and quasi- random studies will be 
excluded. Studies must compare at least two of the inter-
ventions of interest (defined below).
Trial participants
Participants will be women giving birth preterm (before 
37 completed weeks’ gestation) and/or their babies. Indi-
vidually randomised studies will be eligible for inclusion 
if the unit of randomisation was either the woman, or the 
baby. Women and babies will be included regardless of 
whether mode of delivery was vaginal or caesarean, and 
whether the birth was singleton or multiple. Correlations 
between multiples will be accounted for in the analyses. 
Babies will be included regardless of whether or not they 
received immediate resuscitation at birth.
Types of interventions and comparators in pairwise meta-analysis
For the pairwise meta- analysis we will include all trials 
that compare an intervention to enhance umbilical 
blood flow or allow more time for physiological transi-
tion to the comparator immediate cord clamping. This 
includes interventions assessing cord management strat-
egies for timing of cord clamping, and other strategies 
such as cord milking. Trials will be included regardless of 
whether initial neonatal care is provided with the umbil-
ical cord intact, or not. Different strategies (ie, deferred 
cord clamping and cord milking) will be analysed in 
separate subgroups to assess comparability between the 
groups by assessing subgroup effects and heterogeneity. 
They will then be collapsed into one ‘cord management 
intervention’ group if they are deemed comparable based 
on the previous subgroup assessments. If they are deemed 
non- comparable they will be analysed and interpreted 
separately.
Types of interventions and comparators in NMA
For the NMA we will include, as interventions of interest, 
strategies for timing of cord clamping, and other cord 
management strategies to influence umbilical flow and 
placental transfusion.
Thus, interventions of interest include:
 ► Immediate cord clamping without milking (≤15 s or 
trialist defined).
 ► Short deferral of cord clamping (>15 s to <45 s) 
without milking.
 ► Medium deferral of cord clamping (≥45 to <90 s) 
without milking.
 ► Long deferral of cord clamping (≥90 s) without 
milking.
 ► Cord milking or stripping before immediate cord 
clamping (intact cord milking).
 ► Cord milking or stripping before deferred cord 
clamping (intact cord milking).
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Figure 1 Network of possible comparisons between cord management interventions.
 ► Cord milking or stripping after immediate cord 
clamping (cut cord milking).
 ► Cord milking or stripping after deferred cord 
clamping (cut cord milking).
 ► Physiological clamping (clamping after aeration of 
lungs).
If we identify other interventions not listed above we will 
include them if they are addressing cord management or 
related strategies to influence umbilical flow and placental 
transfusion. Again, trials will be included regardless of 
whether initial neonatal care is provided with the umbilical 
cord intact, or not. Studies evaluating collection and storage 
of residual placental blood that is then used for transfu-
sion after birth will be excluded. All possible comparisons 
between eligible interventions are displayed in figure 1. For 
interpretation purposes, immediate cord clamping will act 
as the basis comparison/parameter.
Nodes that specify different timings of cord clamping 
were defined according to what timing is classified as 
immediate clamping, short deferral, medium deferral or 
long deferral according to the literature to date (as shown 
in online supplementary file 1), and after discussion with 
clinicians. Different timings are commonly compared in 
head- to- head comparisons, hence, their classification as 
different intervention nodes. Similarly, nodes that specify 
cord milking were classified after a review of current 
milking techniques described in the literature and after 
discussion with clinicians. If insufficient data are available, 
categories will be collapsed where possible. For instance, 
milking before and after immediate cord clamping could 
be collapsed into one single immediate cord milking 
category, or medium and long delay could be collapsed 
into a medium to long delay category. We consider the 
interventions of interest to be jointly randomisable (ie, 
each participant could, in principle, be randomised to 
any one of the interventions of interest).
Types of outcome measures
Trials must report at least one of the clinical outcomes 
included in this review, as specified in the “measures” 
section below, to be included.
Eligibility for nested prospective meta-analysis
Studies are only included in the nested prospective meta- 
analysis if the investigator/s were blind to outcome data 
by intervention group at the time the main components 
of the protocol (ie, objectives, aims and hypotheses, eligi-
bility criteria, subgroup and sensitivity analyses, and main 
outcomes) were initially agreed in January 2015.
Information sources and search strategy
The search strategy to identify potentially eligible studies 
includes a search of the Cochrane Collaboration Preg-
nancy and Childbirth Review Group’s Trial Register. This 
register contains trials identified from: monthly searches 
of the Cochrane Central Register of Controlled Trials 
(CENTRAL) and CINAHL (EBSCO); weekly searches 
of Medline (Ovid) and Embase (Ovid); hand searches 
of specialty journals and major conferences proceed-
ings; and current awareness alerts from further jour-
nals and BioMed Central. Further details can be found 
elsewhere.50 We will identify ongoing trials that may be 
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eligible by searching for published protocols in Medline 
and Embase, searching online registries of clinical trials, 
and personal contacts (for example, by asking collabora-
tors to notify any unregistered studies they are aware of). 
The Chief Investigators of eligible trials will be invited to 
join the iCOMP Collaboration. They will also be asked if 
they know of any further planned, ongoing or completed 
studies. Databases will be searched from their incep-
tion. Preliminary searches using this search strategy have 
already been completed up to 13 February 2019, but the 
search will be updated regularly to include additional 
trials. The search strategy is outlined in more detail in 
online supplementary file 3.
Selection of studies for inclusion in the review
Two members of the iCOMP Secretariat (see project 
management section below) will independently assess all 
the potentially eligible studies identified for inclusion. 
Disagreements will be resolved by discussion or, if required, 
by consulting a third member of the iCOMP Secretariat. 
Studies that are not willing or able to provide IPD will be 
synthesised where possible using aggregate data.
data collection, management and confidentiality
Data receipt
Each participating trial will be asked to provide deidenti-
fied, individual participant- level data. Clear instructions 
will be provided on which data are needed and the secure 
data transfer process. The preferred data format and 
coding for each variable will be supplied to the investiga-
tors, but data in any format that is most convenient will 
be accepted and recoded if necessary. Data management 
will comply with the University of Sydney Data Manage-
ment Policy 2014. Depending on trialists’ preference, 
data transfer will either take place via secure data transfer 
platforms, or will be shared via institutional secure email 
using password- protected zip files. Data for this project 
will be stored in perpetuity in a password- protected 
folder within the NHMRC (National Health and Medical 
Research Council) Clinical Trials Centre’s network. Only 
authorised project team members working within the 
NHMRC Clinical Trials Centre will have access to these 
data.
Data processing
Data checking: For each trial, range and internal consis-
tency of all variables will be checked. Intervention details 
and missing data will be checked against any protocols, 
published reports and data collection sheets. Integrity 
of the randomisation process will be assessed by exam-
ining the chronological randomisation sequence and 
the balance of participant characteristics across inter-
vention groups. Any inconsistencies or missing data will 
be discussed with the trialists and resolved by consensus. 
Each included study will be analysed separately and the 
results sent to the trial investigators for verification prior 
to inclusion in the iCOMP database. All trial- specific 
outcomes generated from the IPD will be cross- checked 
against published information via a series of crosstabs.
Data recoding: Outcome data may have been collected 
in different formats across trials. Therefore, the deiden-
tified data from each of the trials will be extracted and 
reformatted into a commonly coded data set.
Data transformation and collating: Once the data from 
each of the trials are finalised, they will be combined into 
a single data set, but a trial identifier code for each partic-
ipant will be retained. New variables will be generated 
from the combined data set as required to address the 
hypotheses to be tested.
risk of bias assessment and certainty of evidence appraisal
Eligible studies will be assessed for risk of bias using the 
criteria described in the Cochrane Handbook:51 random 
sequence generation; allocation concealment; blinding 
of participants and personnel; blinding of outcome assess-
ment; incomplete outcome data; selective reporting; and 
other bias. Uncertainties will be resolved where possible 
by contacting study authors. Certainty of evidence will 
be appraised using the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) 
approach52 for the pairwise comparisons, and the rating 
approach suggested by Salanti et al that is implemented 
in the Confidence in Network Meta- Analysis (CINeMA) 
application for the NMA.53
Outcomes measures for pairwise meta-analysis
All outcome measures for the pairwise meta- analysis are 
listed in table 1. The primary outcome will be death of 
the baby prior to hospital discharge. As outcomes for 
babies born very preterm (before 32 weeks’ gestation) 
are different to those born moderately preterm (32–37 
weeks), separate analyses will be conducted for these two 
groups of infants for the secondary outcomes. Where 
possible, definitions will be standardised, otherwise 
outcomes will be used as defined in individual trials. 
Secondary outcomes will include measures of neonatal 
and maternal morbidity, and health service use.
Covariates and subgroups for pairwise meta-analysis
Subgroup analyses will be conducted for the primary 
outcome of death (prior to hospital discharge) and two 
key secondary outcomes (intraventricular haemorrhage 
any grade and any infant blood transfusion). All included 
covariates and subgroups are listed in table 1. The compar-
ative effects of alternative cord management strategies may 
vary depending on key infant risk factors, and/or on the 
level and type of neonatal care available at the hospital 
of birth. Thus, there will be subgroup analyses based on 
participant- level characteristics and based on hospital- level 
characteristics. If data are insufficient for the prespecified 
subgroup analyses, categories will be collapsed.
data analysis for pairwise meta-analysis
The full Statistical Analysis Plan will be agreed on by the 
iCOMP Collaboration before any analyses are under-
taken. Analyses will include all randomised participants 
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Table 1 Measures for individual participant data pairwise meta- analysis
Outcomes
For all infants
Primary outcome Death prior to hospital discharge
For infants born before 32 weeks’ gestation
Key secondary outcomes  ► Death (at any time during follow- up)
 ► Severe intraventricular haemorrhage on cranial ultrasound (grade 3–4)
 ► All grades of intraventricular haemorrhage on cranial ultrasound
 ► Necrotising enterocolitis ≥grade 2 (or trialist definition)
 ► Late- onset sepsis (where possible defined as clinical sepsis >72 hours after birth)
 ► Patent ductus arteriosus requiring treatment (medical and/or surgical)
 ► Chronic lung disease (at 36 weeks’ postmenstrual age or trialist defined)
 ► Blood transfusion (yes/no)
Other secondary outcomes  ► Death (within 7 days)
 ► Other forms of white matter brain injury (eg, periventricular leukomalacia, porencephaly)
 ► Respiratory support (mechanical ventilation, CPAP, low nasal flow oxygen)
 ► Duration of respiratory support
 ► Supplemental oxygen at 36 weeks
 ► Retinopathy of prematurity requiring treatment (medical and/or surgical)
 ► Drug treatment for hypotension (yes/no)
 ► Blood transfusion (number, volume)
 ► Hypothermia on admission to neonatal unit
 ► Haemoglobin
 ► Haematocrit
 ► Polycythaemia
 ► Jaundice requiring treatment
 ► Birth weight
 ► Length of stay in NICU/SCU
 ► Length of stay in hospital
 ► Apgar scores at 1 min and 5 min
 ► Long- term developmental disability (assessed using the Bayley III, and/or other tools):
 – Cerebral palsy
 – Neurodevelopmental disability
 – Score on cognitive scale
 – Score on language scale
 – Score on social/emotional scale
 – Score on motor scale
 – Score on behaviour scale
 – Deafness
 – Blindness
For infants born at or after 32 weeks’ gestation
Key secondary outcomes  ► Death at any time (during follow- up)
 ► Admission to NICU
 ► Blood transfusion (any, number, volume)
Other secondary outcomes  ► Death (within 7 days)
 ► Haemoglobin
 ► Haematocrit
 ► Jaundice requiring treatment
 ► Length of stay in NICU/SCU
 ► Length of stay in hospital
 ► Duration of respiratory support (mechanical ventilation, CPAP, low flow nasal oxygen)
 ► Chronic lung disease
 ► Late- onset sepsis (>72 hours after birth)
 ► Patent ductus arteriosus requiring treatment (medical and/or surgical)
 ► Drug treatment for hypotension
 ► Hypothermia on admission to neonatal unit or postnatal ward
 ► Apgar score at 1 min and 5 min
 ► Long- term developmental disability (assessed using the Bayley III, and/or other tools):
 – Cerebral palsy
 – Neurodevelopmental disability
 – Score on cognitive scale
 – Score on language scale
 – Score on social/emotional scale
 – Score on motor scale
 – Score on behaviour scale
 – Deafness
 – Blindness
Continued
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Outcomes
For all women
Secondary outcomes  ► Maternal death
 ► Postpartum haemorrhage
 ► Postpartum sepsis requiring treatment
 ► Manual removal of placenta
 ► Retained placenta
 ► Not breastfeeding when baby discharged from hospital
 ► Postnatal depression
 ► Blood transfusion
Covariates/subgroups
Participant- level characteristics
   ► Gestation at birth
 ► Type of pregnancy: singleton; multiple
 ► Maternal age
 ► Mode of birth: caesarean before onset of labour; caesarean after onset of labour; vaginal
 ► Onset of labour: spontaneous onset or spontaneous prelabour ruptured membranes; not spontaneous 
onset or spontaneous prelabour ruptured membranes; not known whether spontaneous onset of labour or 
spontaneous prelabour ruptured membranes
 ► Type of breathing onset: spontaneous breathing onset; supported lung aeration (ventilation); unknown
 ► Time of breathing onset relative to cord clamping: before cord clamping/milking; after cord clamping/milking; 
unknown
 ► Sex (male, female, uncertain/other)
 ► Ethnicity (trialist defined)
 ► Small for gestational age (trialist defined): yes/no
 ► Maternal antenatal/intrapartum/postpartum sepsis requiring treatment (trialist defined): yes/no
 ► Assessed as needing resuscitation and/or stabilisation (yes/no)
 ► Type of uterotonic drug (if any)
Hospital/trial- level characteristics
   ► Highest level of neonatal unit available at site: NICU, neonatal unit (some capacity to provide ventilation), 
special care baby unit (no ventilation available), no neonatal unit or special care baby unit
 ► Planned timing of uterotonic drug: before cord clamping; after/at cord clamping; timing mixed or not known
 ► Planned position of the baby relative to the placenta while cord intact: level with placenta (between level of 
woman’s bed and her abdomen/anterior thigh); more than 20 cm below level of placenta; position mixed or 
not known
 ► Need for immediate resuscitation at birth: infants requiring immediate resuscitation at birth excluded; infants 
requiring immediate resuscitation at birth included; unclear whether infants requiring immediate resuscitation 
at birth included or excluded
 ► Type of consent: waiver of consent; deferred consent; informed consent or assent; type of consent unclear
 ► Study year
CPAP, continuous positive airway pressure; NICU, neonatal intensive care unit; SCU, special care unit.
Table 1 Continued
for which data are available, and the primary analyses will 
be based on intention- to- treat. Analyses will be conducted 
using the open- source software R.54
For each outcome, a one- stage approach to analysis 
will be employed to include IPD from all eligible trials 
in a multilevel random- effects or mixed- effects regres-
sion model. Aggregate data will be included where 
IPD are unavailable.55 Relative heterogeneity of treat-
ment effects across trials will be estimated using I2, with 
further inclusion in secondary models of participant- 
level and trial- level covariates to explain the sources of 
heterogeneity. Prediction intervals will be estimated to 
ascertain absolute heterogeneity. Forest plots will be 
presented by trial for the primary outcome, and for any 
secondary outcomes where there is evidence of hetero-
geneity across trials.
We will use a generalised linear modelling framework, 
with the choice of outcome distribution and link func-
tion dependent on outcome type. For example, binomial 
with log link will be used to estimate risk ratios for binary 
outcomes, and Gaussian with identity link for mean differ-
ences, with log- transformation of the data if appropriate. 
We will follow a similar approach for secondary outcomes. 
For estimation of subgroup effects, we will present forest 
plots of pooled treatment effects according to prespeci-
fied subgroup variables, and estimate effects by including 
appropriate interaction terms between a subgroup vari-
able and treatment arm in the regression models. The 
results of all comparative analyses will be presented using 
appropriate estimates of treatment effect along with 95% 
CIs and two- sided p values.
Outcome measures for nMA
The primary outcome for the NMA will be death of the 
baby during the initial hospital stay. If data availability 
permits, IVH (any grade) and blood transfusion (any) 
will be analysed as two key secondary outcomes.
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Covariates and subgroups for nMA
Subgroup analyses will be conducted for the primary 
outcome (death before discharge) and the two key 
secondary outcomes (IVH any grade, blood transfusion). 
Gestational week at birth and highest level of available 
care will be considered as effect modifiers to improve 
consistency of the NMA model. There will be subgroup 
analyses assessing treatment effect by week of gestational 
age, and by comparing babies assessed as in need of 
immediate resuscitation versus not in need of immediate 
resuscitation.
Assessment of the transitivity assumption for nMA
Transitivity in the network will be assured by only including 
interventions that are regarded as jointly randomisable and 
by limiting our sample to preterm infants. Gestational age 
at birth, hospital setting (highest level of available neonatal 
care), as well as study year may act as effect modifiers and 
could influence the transitivity of the network. We will 
therefore investigate whether these variables are distributed 
evenly across comparisons. If we find any of those variables 
to be unevenly distributed, they will be included in the 
network as covariates to investigate their influence on the 
network and on possible inconsistency.
data analysis for nMA
As for the pairwise meta- analysis, all analyses will be 
specified a priori in a full Statistical Analysis Plan, all 
randomised participants for which data are available will 
be included, and the primary analyses will be intention- 
to- treat. Again, aggregate data will be included where IPD 
are unavailable.
We will calculate a two- step random- effects contrast- 
based network meta- regression to compare and rank all 
available interventions for the primary outcome death 
(during initial hospital stay) and for the two key secondary 
outcomes—IVH (any grade) and blood transfusion (any). 
Summary risk ratios with CIs and prediction intervals will 
be presented for each pairwise comparison in a league 
table. We will estimate the ranking probability of each 
intervention being at each rank, and we will use surface 
under the cumulative ranking curve and mean ranks to 
obtain a treatment hierarchy. A frequentist approach 
to analysis will be used. Should models not converge, a 
Bayesian approach will be used instead, setting a weakly 
informative prior d ∼ N (0, 5). Correlations induced by 
multiarm studies will be accounted for using multivariate 
distributions.
As a second step, interactions between key covariates 
and effect estimates will be tested, assuming a common 
interaction across comparisons. If there are statistically 
significant interactions between covariates and treat-
ment effects, we will provide probability rankings of 
intervention effects by subgroup for these covariates. A 
single heterogeneity parameter will be assumed for each 
network. Statistical heterogeneity will be assessed using 
the I2 statistic.
Assessment of inconsistency for nMA
Global consistency will be assessed using the Q statistics 
for inconsistency and the design- by- treatment interaction 
model. Local consistency will be assessed using the loop- 
specific approach and the node- splitting approach to 
explore sources of inconsistency. Since tests of inconsis-
tency are known to have low power, results will be inter-
preted with caution, and potential known sources for 
inconsistency will be explored even if there is no statistical 
evidence of inconsistency. Any detected inconsistency will 
be explored by including covariates specified above (gesta-
tional age at birth, hospital setting, as well as study year) 
into the model, and by excluding potential outlier studies 
in sensitivity analyses. In case of a judgement of excessive 
heterogeneity or inconsistency we would still report the 
resulting parameters, but would interpret the results as not 
reliable.
Assessment of compliance with the allocated intervention
Compliance with the interventions will be described 
for each trial. For studies of early versus deferred cord 
clamping this will be based on (1) The time to cord 
clamping in each allocated group. (2) The difference in 
time between early and deferred clamping. For studies 
comparing cord milking with no milking, this will be 
based on (1) Time to cord clamping in the allocated 
groups. (2) Reported compliance with cord milking in 
both groups.
Assessment of selection bias
We will perform a nested prospective meta- analysis 
as a sensitivity analysis, to detect potential differences 
between prospectively and retrospectively included 
studies that may point to selection or publication bias. 
We expect to also be able to include some unreported 
outcomes sourced from the IPD provided by the included 
studies, which may alleviate selective outcome reporting 
bias.40 Additionally, comparison- adjusted and contour- 
enhanced funnel plots56 will be used to examine whether 
there are differences in results between more and less 
precise studies.
Adjustments for multiplicity
There is only one primary outcome, and few key 
secondary outcomes for this study. For other secondary 
outcomes, no formal adjustments for multiplicity (ie, the 
accumulation of type 1 error and thus higher likelihood 
of chance findings when assessing multiple outcomes) 
are planned. Instead, we will be taking the following 
approach outlined by Schulz and Grimes:57 as secondary 
outcomes examined in this study are interrelated, we will 
interpret the pattern of results, examining consistency of 
results across related outcomes, instead of focusing on 
any single, statistically significant result. All secondary 
outcomes will be reported. Subgroup analyses will be 
performed by testing for interactions and findings will be 
reported as exploratory.58
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Figure 2 Illustration of network of currently available trials comparing different timings of cord clamping.
Planned sensitivity analyses
To assess whether results are robust to trial characteristics 
and methods of analysis, the following sensitivity analyses 
will be conducted for the primary outcome, if data are 
sufficient:
 ► Excluding trials with high risk of bias for sequence 
generation and/or concealment of allocation and/or 
loss to follow- up for pairwise meta- analysis and NMA.
 ► Excluding trials with a significant conflict of interest 
(eg, trials funded by pharmaceutical companies).
 ► For trials comparing early cord clamping with 
deferred clamping, analysis of outcomes weighted by 
degree of separation in mean actual timing of cord 
clamping between intervention and control groups 
for pairwise meta- analysis.
 ► Analysis of outcomes weighted by degree of separa-
tion in haemoglobin (at 24 hours) achieved between 
intervention and control groups for pairwise meta- 
analysis (as a surrogate for net placental transfusion).
 ► For trials with deferred cord clamping, an additional 
dose- response analysis assessing intended time of 
cord clamping deferral as a continuous variable will 
be performed.
 ► Exploratory analysis based on actual, rather than 
intended, timing of cord clamping for individual 
participants for pairwise meta- analysis and NMA.
 ► The impact of missing data on the effects of the 
included interventions for the primary outcome may 
be explored (if appropriate).
Project management
The iCOMP Collaboration will invite membership from 
representatives of each of the included trials contributing 
IPD, have a Secretariat, and invite methodological 
and clinical experts who will form an Advisory Group. 
The Secretariat will be responsible for data collection, 
management and analysis, and for communication within 
the Collaboration.
Public and patient involvement
Two consumer representatives have been invited to join 
the iCOMP collaboration, comment on this protocol and 
be involved in the interpretation of results.
Ethical issues
For each included trial, ethics approval has been previ-
ously granted by their respective Human Research Ethics 
Committees (or equivalent), and informed consent has 
been obtained from all participants. The Chief Investiga-
tors of the included trials remain the custodians of their 
own trial’s data. IPD from the included trials will be deiden-
tified before sharing with the iCOMP Collaboration.
Publication policy
The key methods for this meta- analysis protocol were 
agreed by the iCOMP Collaborators in January 2015, 
before unblinding of any outcome data from the studies 
included in the nested prospective meta- analysis. This 
manuscript was discussed at the iCOMP Collaborators’ 
meeting held at the Paediatric Academic Societies meeting 
in San Diego in April 2015. At this meeting it was agreed 
the protocol should be expanded to include a retrospec-
tive systematic review and IPD and NMA with a nested 
prospective meta- analysis. The protocol was then revised, 
based on further discussion, and circulated to members 
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of the iCOMP Collaboration for further comment and 
agreement prior to manuscript submission.
Participating trialists in the prospective meta- analysis, 
when reporting results from their own trials, will endeavour 
to include a statement that their trial is part of this prospec-
tive meta- analysis in any published manuscripts or confer-
ence abstracts. Any reports of the results of this meta- analysis 
will be published either in the name of the collaborative 
group, or by representatives of the collaborative group on 
behalf of the iCOMP Collaboration, as agreed by members 
of the collaborative group. Draft reports will be circulated to 
the collaborative group for comment and approval before 
submission for publication.
dIsCussIOn
There is an urgency to conduct this systematic review 
and pairwise IPD and NMA so we can make sense of the 
numerous trials currently being undertaken, inform clin-
ical practice and identify the most promising interven-
tions for further evaluation.
This meta- analysis offers an opportunity to reliably test 
important hypotheses that cannot be resolved by any of 
the individual trials, either alone or in simple combina-
tion. Coordinating international efforts in this way will 
help achieve consensus on the most important substan-
tive clinical outcomes to assess in any future trials as 
needed. Unequivocal synthesised results, together with 
the identification of key determinants (eg, effect modi-
fiers), will be critical for translating evidence from this 
meta- analysis directly into practice. Figure 2 shows the 
network of comparisons available from the trials iden-
tified to date. We plan to complete study identification 
and IPD collection by early 2020, then conduct the anal-
yses and disseminate results by mid-2021. Trials that are 
ongoing and therefore unable to provide data by March 
2020 will remain members of the iCOMP collaboration. 
Their data will be included in future updates of iCOMP.
This study is only possible because trialists around 
the world have agreed to collaborate to share the IPD 
from their cord management trials. This collaborative 
approach will enable us to move beyond the traditional 
‘one- size- fits- all’ and towards precision medicine, to 
find the optimal intervention from a range of treatment 
options for each individual woman and her baby, based 
on their individual characteristics and risk factors.
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